Valganciclovir
Valganciclovir, sold under the brand name Valcyte among others, is an antiviral medication used to treat cytomegalovirus (CMV) infection in those with HIV/AIDS or following organ transplant. It is often used long term as it only suppresses rather than cures the infection. Valganciclovir is taken by mouth.
Clinical data | |
---|---|
Trade names | Valcyte, Valcip, others |
AHFS/Drugs.com | Monograph |
MedlinePlus | a605021 |
License data | |
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 60% |
Protein binding | 1–2% |
Metabolism | Hydrolysed to ganciclovir |
Elimination half-life | 4 hours |
Excretion | Kidney |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
NIAID ChemDB | |
PDB ligand | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C14H22N6O5 |
Molar mass | 354.367 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Common side effects include abdominal pain, headaches, trouble sleeping, nausea, fever, and low blood cell counts. Other side effects may include infertility and kidney problems. When used during pregnancy, it causes birth defects in some animals. Valganciclovir is the L-valyl ester of ganciclovir and works when broken down into ganciclovir by the intestine and liver.
Valganciclovir was approved for medical use in 2001. It is on the World Health Organization's List of Essential Medicines. In 2017, a generic version was approved.